Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$7.55 and traded as high as C$8.87. Fennec Pharmaceuticals shares last traded at C$8.87, with a volume of 121 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Stephens raised Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Monday, November 18th.
Get Our Latest Report on FRX
Fennec Pharmaceuticals Stock Up 2.3 %
The firm has a market capitalization of C$248.16 million, a PE ratio of 90.70 and a beta of 0.25. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The firm's 50 day moving average price is C$7.61 and its two-hundred day moving average price is C$7.65.
Insider Activity
In related news, Director Rostislav Christov Raykov purchased 25,000 shares of the company's stock in a transaction that occurred on Friday, December 20th. The stock was acquired at an average price of C$3.87 per share, for a total transaction of C$96,840.00. Also, Senior Officer Robert Christopher Andrade acquired 15,816 shares of Fennec Pharmaceuticals stock in a transaction on Monday, November 18th. The shares were bought at an average price of C$3.43 per share, for a total transaction of C$54,248.88. Insiders acquired 41,612 shares of company stock worth $157,868 over the last ninety days. Corporate insiders own 16.20% of the company's stock.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
